AGXT and metabolic dysfunction-associated steatotic liver disease: Non-alcoholic fatty liver disease (NAFLD), leading to non-alcoholic hepatosteatosis (NASH), apparently down-regulates the activity of the hepatic enzyme alanine-glyoxylate aminotransferase (AGXT), the enzyme which, when mutated, is responsible for primary hyperoxaluria type 1 [91].